1 |
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
Endocrinol Metab.2019;34(3):247-262. Published online 2019 September 26
DOI: http://dx.doi.org/10.3803/EnM.2019.34.3.247
|
|
2 |
New anti-diabetic agents
Doo-Man Kim
J Korean Med Assoc.2017;60(12):992-997. Published online 2017 December 14
DOI: http://dx.doi.org/10.5124/jkma.2017.60.12.992
|
|
3 |
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea
Seungjoon Oh, Suk Chon, Kyu Jeong Ahn, In-Kyung Jeong, Byung-Joon Kim, Jun Goo Kang
Diabetes Metab J.2015;39(3):177-187. Published online 2015 June 15
DOI: http://dx.doi.org/10.4093/dmj.2015.39.3.177
|
|